A Real-World Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α

by | Jul 8, 2026 | Clinical Trials | 0 comments

​ Conditions: Ovarian Cancer; Fallopian Tube Cancers; Primary Peritoneal Cancer

Interventions: Drug: Mirvetuximab Soravtansine (MIRV)

Sponsors: NING LI-GYN

Not yet recruiting Conditions: Ovarian Cancer; Fallopian Tube Cancers; Primary Peritoneal Cancer
Interventions: Drug: Mirvetuximab Soravtansine (MIRV)
Sponsors: NING LI-GYN
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *